Shares of Baxter International (BAX) Sees Large Inflow of Net Money Flow

Baxter International (BAX): $1.32 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.18. The value of trades done on upticks was $8.51 million, whereas, trades done on downticks were valued at $7.19 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.41 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $1.41 million. Baxter International (BAX) fell $0.04 traded at $46.06, a change of -0.09% over the previous day. The stock is -1.52% for the week.


Baxter International (BAX) : Average target price received by Baxter International (BAX) is $48.83 with an expected standard deviation of $5.49. The most aggressive target on the stock is $60, whereas the most downbeat target is $46. 6 financial analysts are currently covering the stock.

Baxter International (NYSE:BAX): stock turned positive on Friday. Though the stock opened at $46.18, the bulls momentum made the stock top out at $46.32 level for the day. The stock recorded a low of $45.67 and closed the trading day at $46.32, in the green by 0.48%. The total traded volume for the day was 2,980,721. The stock had closed at $46.1 in the previous days trading.

In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.